UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000057798
Receipt number R000065849
Scientific Title Real-World Evidence (RWE) Retrospective Chronic Obstructive Pulmonary Disease (COPD) Study among Users of Heated Tobacco Products (HTPs) Diagnosed with COPD Compared to Cigarettes (CIG) Smokers and Former Smokers in Japan
Date of disclosure of the study information 2025/05/09
Last modified on 2026/11/09 11:11:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Real-World Evidence (RWE) Retrospective Chronic Obstructive Pulmonary Disease (COPD) Study among Users of Heated Tobacco Products (HTPs) Diagnosed with COPD Compared to Cigarettes (CIG) Smokers and Former Smokers in Japan

Acronym

RWE Retrospective COPD Study in heated tobacco product users and cigarette smokers diagnosed with COPD

Scientific Title

Real-World Evidence (RWE) Retrospective Chronic Obstructive Pulmonary Disease (COPD) Study among Users of Heated Tobacco Products (HTPs) Diagnosed with COPD Compared to Cigarettes (CIG) Smokers and Former Smokers in Japan

Scientific Title:Acronym

RWE Retrospective COPD Study in heated tobacco product users and cigarette smokers diagnosed with COPD

Region

Japan


Condition

Condition

Chronic Obstructive Pulmonary Disease (COPD)

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of the study is to retrospectively evaluate the impact of having switched from CIG to exclusive use of HTPs (hereafter, exclusive HTP use) on the time to first subsequent COPD-related hospitalization or all-cause mortality compared with continued smoking of CIG (hereafter, exclusive CIG smoking), dual use of CIG and HTP, and quitting of CIG (hereafter, former CIG smoking) among patients who experienced a COPD-related hospitalization (Index Event), after adjusting for sociodemographic and other risk factors.

Basic objectives2

Others

Basic objectives -Others

The primary outcome is about comparative effectiveness.

Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

To compare the time from Index Event to a first subsequent COPD-related hospitalization or all-cause mortality between comparable groups of exclusive HTP users and exclusive CIG smokers.
-Index Event defined as a first COPD-related hospitalization between 1st May 2016 and 31st December 2022.
-The composite endpoint defined as (whichever comes first):
-First subsequent COPD-related hospitalization
-All-cause mortality

Key secondary outcomes

1.To compare the time from Index Event to all-cause mortality between comparable groups of i) exclusive HTP users versus exclusive CIG smokers, ii) exclusive HTP users versus former smokers, and iii) exclusive HTP users versus dual users of CIG and HTP.
Endpoint:
-All-cause mortality

2.To compare the time from Index Event to a first pneumonia-related hospitalization between comparable groups of i) exclusive HTP users versus exclusive CIG smokers, ii) exclusive HTP users versus former smokers, and iii) exclusive HTP users versus dual users of CIG and HTP.
Endpoint:
-Pneumonia-related hospitalization

3.To compare the number and rate of recurrent COPD-related hospitalizations and all-cause hospitalization per year accounting for death as competing risk from Index Event by comparable tobacco exposure groups (exclusive HTP users, dual users of HTP and CIG, and former smokers).
Endpoints:
-Rate and number of COPD-related hospitalizations for each year post-index during the entire observation period
-All-cause hospitalizations for each year post-index during the entire observation period

4.To compare the time from Index Event to the composite endpoint defined above (first subsequent COPD-related hospitalization or all-cause mortality) between comparable groups of i) exclusive HTP users versus former smokers and ii) exclusive HTP users versus dual users of CIG and HTP.
Endpoint:
Composite endpoint defined as (whichever comes first):
-First subsequent COPD-related hospitalization
-All-cause mortality

5.To evaluate whether the time from Index Event to a first subsequent COPD-related hospitalization or all-cause mortality for exclusive HTP users vs exclusive CIG smokers varies for exclusive HTP users by the number of years of switching (<1 year, 1-3 years, >3 years).
Endpoint:
Composite endpoint defined as (whichever comes first):
-First subsequent COPD-related hospitalization
-All-cause mortality


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

-Patients with any healthcare encounter records in the Tokushukai Medical Database
-Patients with a record of Index Event (first COPD-related hospitalization between the 1st of May 2016 and the 31st of December 2022)
-Age 40 year or older at the time of the Index Event
-Patients of any gender
-Patients or relatives who are able to understand the information provided in the ICF and have signed it.

Key exclusion criteria

-Tobacco industry employees or their first-degree relatives
-Employees of Philip Morris International (PMI) and its affiliate companies, Tokushukai Medical Corporation, 3H Medi Solution, or Syneos Health Clinical K.K.
-Patients who have had five or more COPD-related hospitalizations in the 12 months prior to the Index Event
-Never smokers (this population was excluded because the prevalence of never smoking is extremely low among COPD patient population).
-Patients having any of the following diseases prior to the Index Event: bronchiectasis, active tuberculosis (defined as a tuberculosis diagnosis in the 12 months prior to Index Event), cystic fibrosis, pulmonary fibrosis, pulmonary embolism, lung cancer.

Target sample size

9638


Research contact person

Name of lead principal investigator

1st name Makoto
Middle name
Last name Hibino

Organization

Tokushukai Medical Corporation Shonan-Fujisawa Tokushukai Hospital

Division name

Respiratory Medicine

Zip code

251-0041

Address

1-5-1 Tsujidokandai, Fujisawa-shi, Kanagawa, Japan

TEL

0466-35-1177

Email

m-hibino@ctmc.jp


Public contact

Name of contact person

1st name Takashi
Middle name
Last name Sato

Organization

Syneos Health Clinical K.K.

Division name

Clinical Operations/Real World and Late Phase

Zip code

100-7012

Address

12F JP Tower, 2-7-2 Marunouchi, Chiyoda-ku, Tokyo, Japan

TEL

03-6733-9690

Homepage URL


Email

takashi.sato@syneoshealth.com


Sponsor or person

Institute

Philip Morris Products S.A.

Institute

Department

Personal name



Funding Source

Organization

Philip Morris Products S.A.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Switzerland


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Tokushukai Group Ethics Committee

Address

Tokyodo Chiyoda Bldg. 15F, 1-3-1, Kudan-minami, Chiyoda-ku, Tokyo, Japan

Tel

03-3263-4801

Email

mirai-ec1@mirai-iryo.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

徳洲会グループ/ Tokushukai Group


Other administrative information

Date of disclosure of the study information

2025 Year 05 Month 09 Day


Related information

URL releasing protocol

Not applicable.

Publication of results

Unpublished


Result

URL related to results and publications

Not applicable.

Number of participants that the trial has enrolled

2298

Results

Of the 2,298 patients who signed the informed consent form, 1,305 met the eligibility criteria and were included in the study. Among the 1,305 patients, 236 (18.1%) were exclusive cigarette (CIG) smokers, 24 (1.8%) were exclusive HTP users, 12 (0.9%) were dual users of CIG and HTPs, and 1,033 (79.2%) were former smokers at the date of Index Event, defined as the discharge date of an initial COPD-related hospitalization.

Results date posted

2026 Year 09 Month 07 Day

Results Delayed


Results Delay Reason

Not applicable. There were no delays in result reporting.

Date of the first journal publication of results


Baseline Characteristics

Among the 1,305 patients included in the study, 236 (18.1%) were exclusive CIG smokers, 24 (1.8%) were exclusive HTP users, 12 (0.9%) were dual users of CIG and HTP, and 1,033 (79.2%) were former smokers. Most of the questionnaire data was self-reported by the patients themselves (68.0%, n=888).

The median age at the date of Index Event was 75.0 years (Q1: 69.0, Q3: 82.0). By tobacco exposure groups, the median age was 72 years (Q1: 64.0, Q3: 78.0) for exclusive CIG smokers, 66 years (Q1: 56.5, Q3: 74.0) for exclusive HTP users, 65.5 years (Q1: 52.0, Q3: 75.5) for dual users of CIG and HTP, and 76 years (Q1: 70.0, Q3: 83.0) for former smokers in the unadjusted (unweighted) analysis.

A total of 1,162 (89%) patients were males. The median pack-years of CIG smoking prior to index for all exposure groups combined was 50.8 (Q1: 30.0, Q3: 73.5). Among the exposure groups, the median pack-years of CIG smoking prior to index was 47.9 (Q1: 31.9, Q3: 78.0) in the exclusive CIG smokers, 35.9 (Q1: 28.5, Q3: 55.8) in the exclusive HTP users, 52.5 (Q1: 36.3, Q3: 87.8) in the dual users of CIG and HTP, and 52.5 (Q1: 29.0, Q3: 72.0) in the former smokers in the unadjusted (unweighted) analysis.

Participant flow

A total of 29,580 potentially eligible patients (including those deceased) were identified in the Tokushukai Medical Database. They were contacted by post to probe their interest in participating in the study. Of those, 2,298 patients consented (either personally or through a relative / legal guardian) to participate in the study and were enrolled into the study. Of the enrolled patients, 1,305 met all eligibility criteria and were included in the study. A total of 993 patients were not included in the study for the following reasons:
18 patients had inaccurate assessment of eligibility criteria,
554 patients were excluded from the analysis as they could not be assigned to any tobacco exposure group due to missing information from the questionnaires.
421 patients were classified as never smokers at the date of Index Event, thus not meeting the eligibility criteria.

Adverse events

Not applicable. This was a retrospective cohort study, with no active follow-up of patients. Therefore, no information on adverse events was collected.

Outcome measures

Primary (Main) Outcome: time between first chronic obstructive pulmonary disease (COPD)-related hospitalization and subsequent COPD-related hospitalization or all-cause mortality.
Of the 2,298 patients who signed the informed consent form, 1,305 met the eligibility criteria and were included in the study. Among the 1,305 patients, 236 (18.1%) were exclusive cigarette (CIG) smokers, 24 (1.8%) were exclusive HTP users, 12 (0.9%) were dual users of CIG and HTPs, and 1,033 (79.2%) were former smokers at the date of Index Event, defined as the discharge date of an initial COPD-related hospitalization.

Exclusive CIG smoking was defined as smoking at least one CIG per day on average and no use of HTPs, or using less than one HTP consumable per day, at the date of the Index Event. Exclusive HTP use was defined as the use of at least one HTP consumable per day on average with no CIG smoking, or smoking less than one CIG per day, at the date of the Index Event.

The analysis was descriptive, as the number of patients in the different tobacco exposure groups was low. This precluded hypothesis testing and comparative analyses of the composite endpoint between exposure groups.

The unadjusted median follow-up time was 1.71 years (Q1: 0.22, Q3: 3.82) overall, 1.07 years (Q1: 0.15, Q3: 2.97) among exclusive HTP users, and 0.97 years (Q1: 0.13, Q3: 3.34) among exclusive CIG smokers.

Overall, 499 patients (38.2%) had a first subsequent COPD-related hospitalization or all-cause mortality during follow-up, including 5 of 24 exclusive HTP users (20.8%) and 76 of 236 exclusive CIG smokers (32.2%). The unadjusted median time to the composite endpoint was 8.9 months for exclusive HTP users and 5.3 months for exclusive CIG smokers.

Propensity score weighting was applied to adjust for age, sex, and length of the COPD-related hospitalization at the date of Index Event. Due to the sample size limitations, only these variables could be selected for statistical adjustment, and those variables were appraised to be the most relevant.

The weighted percentage of patients without the composite endpoint at the end of Year 1 of follow-up was 82% (95% confidence interval [CI]: 53.5, 93.9) for exclusive HTP users and 76.4% (68.2, 82.7) for exclusive CIG smokers. By Year 5, only two patients in each exposure group were still without the composite endpoint or uncensored, patients remaining under observation.


Secondary Outcomes
Time until the all-cause mortality between HTP users and all other tobacco exposure groups
Among the 1,305 patients, 329 (25.2%) died during the follow-up period, 68 (28.8%) of whom were exclusive CIG smokers, 1 (4.2%) exclusive HTP user, 3 (25.0%) dual users of CIG and HTP, and 257 (24.9%) former smokers. The low number of events among the HTP user group precluded any further analysis for this endpoint.

Time until pneumonia-related hospitalization between HTP users and all other tobacco exposure groups
One of 24 (4.2%) exclusive HTP users experienced pneumonia-related hospitalization during the follow-up period. Due to the low event count, estimation of cumulative incidence was not feasible. Nineteen of 236 (8.1%) exclusive CIG smokers, 1 of 12 (8.3%) dual users of HTP and CIG, and 164 of 1,033 (15.9%) former smokers experienced pneumonia-related hospitalization during the follow-up period.

Rate of recurrent COPD-related hospitalizations per year
The rate for recurrent COPD-related hospitalizations, weighted for age, sex, and length of the COPD-related hospitalization at the date of Index Event, was 1.03 per 10 person-years (95% CI: 0.43, 2.48) among exclusive HTP users, 1.37 per 10 person-years (95% CI: 0.29, 6.44) among dual users of CIG and HTP, 1.75 per 10 person-years (95% CI: 1.31, 2.36) among exclusive CIG smokers, and 2.01 per 10 person-years (95% CI: 1.81, 2.23) among former smokers.

Rate of recurrent all-cause hospitalizations per year
The rate for recurrent all-cause hospitalizations, weighted for age, sex, and length of the COPD-related hospitalization at the date of Index Event, was 3.42 per 10 person-years (95% CI: 1.93, 6.05) among exclusive HTP users, 4.40 per 10 person-years (95% CI: 3.52, 5.50) among exclusive CIG smokers, 4.58 per 10 person-years (95% CI: 1.17, 17.94) among dual users of CIG and HTP, and 4.59 per 10 person-years (95% CI: 4.27, 4.94) among former smokers.

Composite endpoint of first subsequent COPD-related hospitalization or all-cause mortality comparing exclusive HTP users with other tobacco exposure groups
Prior to propensity score weighting, the composite endpoint was observed in 2 of 12 (16.7%) dual users of CIG and HTP, and 416 of 1,033 (40.3%) former smokers. The limited number of events among the dual users of CIG and HTP group precluded any further analysis.

Regarding exclusive HTP users and former smokers, the unadjusted median time to the composite endpoint was 8.9 months for exclusive HTP users and 12.2 months for former smokers. Time-to-event estimates, weighted for age, sex, and length of the COPD-related hospitalization at the date of Index Event, for exclusive HTP users and former smokers had wide and overlapping 95% CI indicative of the small number of exclusive HTP users and the low number of events.

The analysis on whether the time from Index Event to subsequent COPD-related hospitalization or all-cause mortality for exclusive HTP users versus exclusive CIG smokers varies by the number of years of HTP use could not be performed due to the low number of enrolled exclusive HTP users.

Plan to share IPD

The study sponsor is committed to transparency and will consider any requests for underlying data, provided that such data may be shared under applicable laws.

IPD sharing Plan description

Refer to the section "Plan to share IPD."


Progress

Recruitment status

Completed

Date of protocol fixation

2024 Year 08 Month 06 Day

Date of IRB

2024 Year 08 Month 13 Day

Anticipated trial start date

2024 Year 12 Month 09 Day

Last follow-up date

2025 Year 04 Month 30 Day

Date of closure to data entry

2025 Year 06 Month 30 Day

Date trial data considered complete

2025 Year 08 Month 31 Day

Date analysis concluded

2025 Year 12 Month 29 Day


Other

Other related information

It is expected that there will be a difference in the time from Index Event to a first subsequent COPD-related hospitalization and all-cause mortality between smokers who switched to exclusive use of HTP and those that continued to smoke CIG exclusively. The findings on the time from Index Event to a first subsequent COPD-related hospitalization and all-cause mortality in exclusive HTP users compared to dual users of CIG and HTP and former smokers will also be reported. The results of the study will be released in the first quarter of 2026.


Management information

Registered date

2025 Year 05 Month 08 Day

Last modified on

2026 Year 11 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000065849